TARDBP/TDP-43 Protein

TARDBP/TDP-43 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TARDBP/TDP-43 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TARDBP</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TARDBP/TDP-43</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=TARDBP" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-4fabd9ce" style="color:#ce93d8" title="Score: 0.46">Cryptic Exon Silencing Restoration...</a><br><a href="/hypothesis/h-eea667a9" style="color:#ce93d8" title="Score: 0.45">Cross-Seeding Prevention Strategy...</a><br><a href="/hypothesis/h-7693c291" style="color:#ce93d8" title="Score: 0.44">RNA-Binding Competition Therapy for TDP-...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">670 edges</a></td>
</tr>
</table>

TARDBP/TDP-43 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TARDBP/TDP-43 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TARDBP</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TARDBP/TDP-43</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=TARDBP" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-4fabd9ce" style="color:#ce93d8" title="Score: 0.46">Cryptic Exon Silencing Restoration...</a><br><a href="/hypothesis/h-eea667a9" style="color:#ce93d8" title="Score: 0.45">Cross-Seeding Prevention Strategy...</a><br><a href="/hypothesis/h-7693c291" style="color:#ce93d8" title="Score: 0.44">RNA-Binding Competition Therapy for TDP-...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">670 edges</a></td>
</tr>
</table>

[TDP-43](/proteins/tdp-43) (TAR DNA-binding protein-43, encoded by the TARDBP gene) is a heterogeneous nuclear ribonucleoprotein (hnRNP) that plays critical roles in RNA processing, including splicing, stability, transport, and translation. Pathological aggregation of [TDP-43](/mechanisms/tdp-43-proteinopathy) in [neurons](/entities/neurons) and glia is the hallmark of amyotrophic lateral sclerosis (ALS) and the majority of frontotemporal dementia (FTD) cases, making TDP-43 one of the most important proteins in neurodegenerative disease research.

Introduction

TDP-43 is a 414-amino acid protein that belongs to the hnRNP family. Originally characterized as a transcriptional repressor binding to the TAR element of HIV-1, TDP-43 has emerged as a fundamental RNA-binding protein with roles in nearly every aspect of RNA metabolism. The discovery of TARDBP mutations as a cause of familial ALS in 2008 established TDP-43 as a central player in neurodegeneration. This page provides comprehensive information about TDP-43's structure, functions, disease mechanisms, and therapeutic strategies. [@kwiatkowski2009]

[@gassetrosa2019]

Molecular Structure

Domain Architecture

TDP-43 contains several distinct functional domains:

• N-terminal domain (residues 1-102): Contains a nuclear localization signal (NLS) and mediates protein-protein interactions. This domain is relatively conserved and participates in homodimerization.
• RNA recognition motif 1 (RRM1, residues 106-176): The primary RNA-binding domain with the canonical RNP1 and RNP2 sequences. Binds UG-rich RNA sequences with high affinity.
• RNA recognition motif 2 (RRM2, residues 191-259): A second RRM that contributes to RNA binding specificity and affinity. The two RRMs work cooperatively.
• Glycine-rich low-complexity domain (residues 274-414): This C-terminal region is prion-like and prone to aggregation. Contains the QGSY region (Gln-Gly-Ser-Tyr) characteristic of many RNA-binding proteins. Most ALS/FTD mutations cluster here.
• Nuclear export signal (NES): A leucine-rich sequence enabling cytoplasmic localization under certain conditions.

Post-Translational Modifications

TDP-43 undergoes numerous modifications:

• Phosphorylation: At S379, S403, S404, and S409/S410 (the most studied sites) in pathological inclusions
• Ubiquitination: Pathological aggregates are ubiquitinated
• SUMOylation: Affects subcellular localization
• Acetylation: At K263, K331, affects RNA binding
• Methylation: Arginine methylation affects localization and function

Normal Physiological Functions

RNA Processing

Alternative Splicing

TDP-43 regulates alternative splicing of numerous transcripts:

• CFTR exon 9: Classic example of TDP-43-mediated skipping
• neuronal transcripts: Including [tau](/proteins/tau) (MAPT), GABA receptors, and others
• [APOE](/proteins/apoe-protein) exon 2: Tissue-specific regulation

RNA Stability and Turnover

• Binds to 3' UTRs of target mRNAs
• Regulates mRNA stability through interaction with decay pathways
• Influences mRNA half-life in the cytoplasm

RNA Transport and Localization

• Associated with RNA granules in dendrites
• Regulates local translation in neurons
• Participates in synaptic plasticity through RNA localization

Transcription Regulation

• Originally identified as a transcriptional repressor (TAR DNA-binding protein)
• Binds to single-stranded DNA and RNA
• Modulates transcription of multiple genes

Nuclear-Cytoplasmic Shuttling

TDP-43 dynamically shuttles between nucleus and cytoplasm:

• NLS-mediated nuclear import
• CRM1-dependent nuclear export
• Shuttling is activity-dependent
• Dysregulation of shuttling is an early event in disease

Role in Disease

Amyotrophic Lateral Sclerosis (ALS)

Genetics

Over 50 pathogenic TARDBP mutations have been identified in ALS:

• Missense mutations: Predominantly in the glycine-rich domain (e.g., A315T, G348C, N345K, M337V)
• Truncation mutations: Leading to loss of function
• ALS/FTD overlap: Some mutations cause both ALS and FTD

Pathogenic Mechanisms

• Impaired RNA processing of essential neuronal transcripts
• Disrupted splicing of synaptic proteins
• Altered stress granule dynamics

• Aggregation into cytoplasmic inclusions
• Sequestration of other RNA-binding proteins
• Disrupted RNA granule transport

• TDP-43 is a component of stress granules
• Persistent stress granule formation may seed pathology
• Impaired stress granule clearance in disease

• Nuclear envelope disruption
• Imported retention in cytoplasm
• Loss of nuclear function

Frontotemporal Dementia (FTD)

• FTD-TDP type: Most common subtype of FTD
• Pathology: TDP-43 inclusions in frontal and temporal cortices
• Genetics: TARDBP mutations cause familial FTD in rare cases
• Overlap with ALS: Many FTD cases show motor neuron involvement

Other Neurodegenerative Diseases

• Alzheimer's disease: TDP-43 pathology in ~50% of AD cases
• Parkinson's disease: TDP-43 inclusions in some PD/DLB cases
• Huntington's disease: Co-pathology in some HD cases

Animal Models

Genetic Models

• TARDBP knockout mice: Viable with mild neurological phenotypes
• Transgenic TDP-43: Expressing wild-type or mutant human TDP-43
• Conditional models: Inducible expression systems

Key Findings from Models

• Mutant TDP-43 causes motor neuron degeneration
• Wild-type TDP-43 overexpression can be toxic
• Loss of TDP-43 function disrupts splicing of critical genes
• ALS-linked mutations enhance aggregation propensity

Therapeutic Strategies

Targeting TDP-43 Aggregation

• Aggregation inhibitors: Small molecules preventing fibril formation
• Modulators of liquid-liquid phase separation: Targeting LLPS dynamics
• Antibodies: Against aggregated TDP-43

RNA-Targeted Approaches

• ASOs targeting TARDBP mRNA: Reduce total TDP-43 levels
• Splicing modifiers: Correct aberrant splicing events
• RNA granule modulators: Affect stress granule dynamics

Gene Therapy

• Gene silencing: AAV-delivered shRNA or ASOs
• CRISPR approaches: Allele-specific editing
• Protein replacement: Not feasible due to size

Neuroprotective Strategies

• Mitochondrial protectants: Address energy dysfunction
• Cytoprotective agents: Enhance cellular stress responses
• Anti-inflammatory approaches: Target neuroinflammation

Research Directions

• Phase separation biology: Understanding LLPS in health and disease
• Biomarkers: Developing TDP-43 in CSF or blood as a biomarker
• Structural biology: Cryo-EM of TDP-43 fibrils
• Patient-derived models: iPSC neurons and organoids

Cross-Pathology Connections

With ALS Genes

• FUS: Similar RNA-binding protein pathology
• [C9orf72](/entities/c9orf72): Dipeptide repeats affect TDP-43 function
• SOD1: Shares mitochondrial dysfunction pathways
• OPTN/TBK1: [Autophagy](/entities/autophagy) genes affecting TDP-43 clearance

With FTD Genes

• GRN: Progranulin and TDP-43 have intersecting pathways
• FTD-TDP types: Share pathological mechanisms

Background

The study of Tardbp Tdp 43 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Brain Atlas Resources

• [Allen Human Brain Atlas - TARDBP Expression](https://human.brain-map.org/microarray/search/show?search_term=TARDBP)
• [Allen Cell Type Atlas - TARDBP](https://celltypes.brain-map.org/)
• [BrainSpan - TARDBP Developmental Expression](https://brainspan.org/)
• [Allen Mouse Brain Atlas - TARDBP](https://mouse.brain-map.org/)

References